

SWISS EQUITIES – STRUCTURAL VALUE CREATION

White Paper

For Professional Investors in Switzerland or Professional Investors as defined by the relevant laws

Asset Management | June 2020




UNION BANCAIRE PRIVÉE

Key points

- ◆ *The resilience of the Swiss economy has once again been proved during the COVID-19 pandemic and is reflected by the Swiss equity market's year-to-date outperformance.*
- ◆ *Several Swiss companies across all market cap segments have benefited from the disruption caused by the pandemic, as they have exposure to structural long-term trends which were accelerated by the crisis.*
- ◆ *However, the strongest argument for a Swiss equity allocation within a diversified equity portfolio remains the long-term structural outperformance of Swiss equities driven by their superior value creation and ESG profiles.*
- ◆ *An active investment approach driven by fundamentals and supported by extensive expertise and knowledge of the market, has led to an impressive track record and substantial AUM growth for UBP's Swiss equity franchise over the last fourteen years.*

major global and regional indices, both year-to-date and over the longer term.

Performance of major equity markets (%)



Sources: UBP and, Bloomberg Finance LP., Data as at May 2020. Past performance is not a guide for to current or future results.

Switzerland and COVID-19

In early June 2020, the Deep Knowledge Group, a consortium of companies and non-profit organisations, issued an update on their COVID-19 Regional Safety Assessment report (<https://www.dkv.global/covid-19/full-report>), which uses a host of data points to rank the COVID-19 safety and risk assessments of 200 countries. Switzerland received the highest overall score for the effective measures it put in place to stop the spread of the virus, combined with the underlying quality of the nation's medical system and the resilience of the country's economy.

As in previous crises, the safe-haven status of the Swiss franc and an inflation rate of only 0.2% (as at the end of 2019) have contributed to weathering this storm in the past few months. Switzerland has an independent central bank which operates free of political pressure. The Swiss National Bank has been working with negative interest rates since 2015 and has intervened in foreign exchange markets when necessary to absorb external shocks and ease upside pressure on the Swiss franc.

Switzerland's fiscal stability has allowed the country's parliament to swiftly provide a substantial aid package of CHF 57 billion to support the domestic economy. In addition, the Swiss loan programme, which was developed through close collaboration between the government and Swiss banks to offer SMEs quick and simple access to loans to cover their immediate liquidity needs, has won international acclaim.

Over the first few volatile months of 2020, the Swiss equity market reflected the solid standing of the country and its companies, outperforming most major global equity markets by limiting downside while at the same time participating in strong upward moves. The SPI Extra, the Swiss small- and mid-cap index, has shown similar resilience compared with

The 2020 EPS growth estimate for global equities dropped further to -17% over the course of May compared with -10% at the end of April, while the 2021 estimate now stands at +26%. Expected earnings growth rates by region for 2020 range from +2% for China to -26% for the eurozone and -23% for the US; for Switzerland analysts expect a comparatively benign decline in EPS of -8%.

Swiss companies are innovation leaders in various industries, probably most visibly in medical technologies. Close to 700 Swiss companies specialise in this field, ranging from big players, such as Novartis, Roche and Lonza, to listed small- and mid-sized companies, such as Tecan, Vifor Pharma and Straumann, to a host of privately-owned companies.

The healthcare sector in Switzerland has been a strong performer year-to-date, boosted by positive news on companies, such as Lonza and Roche, both of whom are potential beneficiaries of developments in the COVID-19 situation. Lonza (up 34% year-to-date) is the best contributor to the SPI's performance over 2020. While the company has suffered minor supply disruptions linked to COVID-19, a deal with Moderna to become their manufacturing partner in the development of a COVID-19 vaccine has driven the share price in the short term. In the long term, Lonza will remain a key beneficiary of the structural trend towards more outsourcing in the pharmaceutical industry.

In the small- and mid-cap segment, the IT company Logitech and medical lab supplier Tecan have been the strongest contributors to the SPI Extra's year-to-date performance. Apart from these names, several other beneficiaries of positive newsflow can be found in the Swiss market across both sectors and market caps.

Structural, long-term value creation

Despite its small size in terms of geography, Switzerland ranks fifth in the MSCI AC World, with a 3% weighting and a total market capitalisation over CHF 1.3 trillion as at May 2020. Swiss equities offer a lower correlation to global equities and are supported by a strong underlying currency, which can benefit investors who seek real returns. Most sectors and companies have adapted to the currency's strength; for instance, the pharmaceutical industry, which accounts for a significant share of exports, boosts high pricing power, as it is less affected by short-term economic fluctuations. Some small- and mid-cap names are indispensable to their large global customers and have cemented leading market positions in their respective industries.


Global industry leaders in the Swiss SMID segment



Sources: UBP and company reports. For illustrative purposes only. This is not an indication to buy or sell. Data as at May 2020.

As mentioned previously, Swiss equities, especially in the small- and mid-cap segment, tend to outperform global equities over both short and longer periods of time. Contrasting these superior relative returns with the relative volatility incurred underlines the attractiveness of Swiss equities even more, as they deliver one of the highest risk-adjusted returns among major equity markets.

Long term outperformance, SPI and SPI Extra vs MSCI AC World




Sources: UBP and Bloomberg Finance LP. Data as at May 2020. Past performance is not a guide to current or future results.

Union Bancaire Privée, UBP SA

Rue du Rhône 96-98 | P.O. Box 1320 | 1211 Geneva 1 | Switzerland | www.ubp.com

Risk-adjusted return matrix of major equity markets, in local currencies, over fifteen years




Sources: UBP and Bloomberg Finance LP. Total returns shown in local currencies from 31 May 2005 to 31 May 2020. Past performance is not a guide to current or future results.

This structural outperformance is linked to the high level of value creation, as measured by the spread of the cash flow return on investment (CFROI) over the cost of capital in the Swiss & Global Equity team's investment framework. Switzerland has historically, and until recently, delivered consistently high CFROI spreads compared with other regional markets. It is worth noting that the quality and value creation potential of the small- and mid-cap segment has been improving over recent years, which was reflected by its strong outperformance over the period.

As passive investment options in Swiss equities are somewhat limited and concentrated on large caps, an active investment approach is the best way to gain exposure to the substantial value-creation potential of the small- and mid-cap segment. As the segment is much less covered by sell-side analysts than the companies in the SMI, there are also ample alpha opportunities that can be exploited by active managers with the experience and expertise of UBP's Swiss equity franchise.

Structural value creation profiles



As at June 2020, UBP's range of active Swiss equity strategies (UCITS and Swiss contractual fund structures) built on the CFROI life-cycle framework, has a track record of fourteen years for the flagship Swiss Equity strategy, and five years for the Swiss Small- and Mid-Cap strategy (since 30 June 2006 and 30 June 2015 respectively). Both strategies show sustainable, superior value-creation profiles compared with their respective benchmarks, as well as superior ESG profiles, with AA ratings for both, and an MSCI ESG quality score above 7.5.

The historical sector breakdown of the strategies shows a consistent and balanced allocation to sectors over time, while stock selection has always been the main driver of performance for both funds. A fundamental bottom-up investment process is key to delivering superior value

creation over both the short and long term. UBP's Swiss equity strategies remain well positioned for short-term momentum, as well as long-term structural drivers, without the need to time markets or themes.

The Swiss & Global Equity team,
Union Bancaire Privée, UBP SA
Rue du Rhône 96-98 | P.O. Box | CH-1211 Geneva 1
T +41 58 819 21 11



 Please consider the environment before printing.

Source: Holt, Credit Suisse, UBP, as of 31.05.2020.

Disclaimer

This is a marketing document and is intended for informational and/or marketing purposes only. This document is confidential and intended only for the use of the person(s) to whom it was delivered. It may not be reproduced (in whole or in part) or delivered, given, sent or in any other way made accessible to any other person without the prior written approval of Union Bancaire Privée, UBP SA or any entity of the UBP Group ("UBP"). This document reflects the opinion of UBP as of the date of issue. This document is for distribution only to persons who are Professional Investors in Switzerland, or Professional Clients or an equivalent category of investors as defined by the relevant laws (all such persons together being referred to as "relevant persons"). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. It is not intended for distribution, publication, or use, in whole or in part, in any jurisdiction where such distribution, publication, or use would be unlawful, nor is it directed at any person at whom or entity at which it would be unlawful to direct such a document. In particular, this document may not be distributed in the United States of America and/or to US persons (including US citizens residing outside the United States of America). This document has not been produced by UBP's financial analysts and is not to be considered financial research. It is not subject to any guidelines on financial research and independence of financial analysis. Reasonable efforts have been made to ensure that the content of this document is based on information and data obtained from reliable sources. However, UBP has not verified the information from third sources in this document and does not guarantee its accuracy or completeness. UBP makes no representations, provides no warranty, and gives no undertaking, express or implied, regarding any of the information, projections or opinions contained herein, nor does it accept any liability whatsoever for any errors, omissions or misstatements. The information contained herein is subject to change without prior notice. UBP gives no undertaking to update this document or to correct any inaccuracies in it which may become apparent. This document may refer to the past performance of investment interests. Past performance is not a guide to current or future results. The value of investment interests can fall as well as rise. Any capital invested may be at risk and investors may not get back some or all of their original capital. Any performance data included in this document does not take into account fees, commissions, and expenses charged on issuance and redemption of securities, nor any taxes that may be levied. Changes in exchange rates may cause increases or decreases in investors' returns. All statements other than statements of historical fact in this document are "forward-looking statements". Forward-looking statements do not guarantee future performances. The financial projections included in this document do not represent forecasts or budgets, but are purely illustrative examples based on a series of current expectations and assumptions which may not eventuate. The actual performance, results, financial condition and prospects of an investment interest may differ materially from those expressed or implied by the forward-looking statements in this document as the projected or targeted returns are inherently subject to significant economic, market and other uncertainties that may adversely affect performance. UBP also disclaims any obligation to update forward-looking statements, as a result of new information, future events or otherwise. None of the contents of this document should be construed as advice or any form of recommendation to purchase or sell any securities or funds. This document does not replace a prospectus or any other legal documents, which can be obtained free of charge from the registered office of the fund they relate to, or from UBP. The opinions herein do not take into account individual investors' circumstances, objectives, or needs. Each investor must make his/her own independent decision regarding any securities or financial instruments mentioned herein and should independently determine the merits or suitability of any investment. In addition, the tax treatment of any investment in the fund(s) mentioned herein depends on each individual investor's circumstances and may be subject to change in the future. Investors are invited to carefully read the risk warnings and the regulations set out in the prospectus or other legal documents and to seek professional financial, legal and tax advice. This document should not be deemed an offer nor a solicitation to buy, subscribe to, or sell any currency, funds, products, or financial instruments, to make any investment, or to participate in any particular trading strategy in any jurisdiction where such an offer or solicitation would not be authorised, or to any person to whom it would be unlawful to make such an offer or solicitation. Telephone calls to the telephone number stated in this document may be recorded. UBP will assume that by calling this number you consent to such recording. UBP is authorised and regulated in Switzerland by the Swiss Financial Market Supervisory Authority and is authorised in the United Kingdom by the Prudential Regulation Authority. UBP is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority.